US EditionPublished • loading... • Updated
Researchers develop affordable, rapid blood test for brain cancer
The biochip detects active EGFR biomarkers using a 100-microliter blood sample in under an hour, offering a faster, less invasive glioblastoma monitoring method.
- On Saturday, University of Notre Dame researchers unveiled an automated device diagnosing glioblastoma in under an hour, validated in more than 40 brain cancer patients with blood samples from the Olivia Newton-John Cancer Research Institute, Melbourne.
- Because glioblastoma grows aggressively, clinicians say it is deadly due to its brain location, with average patient survival ranging from 12 to 18 months and severe cases about 14 months.
- The electrokinetic biochip uses synthetic silica nanoparticles to `report` active EGFRs on extracellular vesicles, creating a high negative charge that produces a measurable voltage shift.
- For patients in regional areas, a simple blood test could improve treatment outcomes and reduce invasive procedures, benefiting about 2,000 Australians diagnosed annually with high-grade brain cancers.
- Researchers say the adaptable platform could detect biomarkers for multiple diseases, while the <$2 disposable chip and automated platform enable wider trials with backing from the National Institutes of Health Common Fund and collaborators including Vanderbilt University and Olivia Newton-John Cancer Research Institute.
Insights by Ground AI
16 Articles
16 Articles
Newcastle Herald+2 Reposted by 2 other sources
'A window to the brain': crucial blood test developed with Mark Hughes funds
A new blood test for brain cancer was developed with the biobank of the Mark Hughes Foundation Centre for Brain Cancer Research at the University of Newcastle.
·Newcastle, Australia
Read Full Article
Researchers develop affordable, rapid blood test for brain cancer
Researchers have developed a novel, automated device capable of diagnosing glioblastoma, a fast-growing and incurable brain cancer, in less than an hour. The average glioblastoma patient survives 12-18 months after diagnosis.
·United States
Read Full Article
A simple blood test has the potential to improve the lives of brain cancer patients and increase their already extremely low survival rate.
Coverage Details
Total News Sources16
Leaning Left9Leaning Right1Center3Last UpdatedBias Distribution69% Left
Bias Distribution
- 69% of the sources lean Left
69% Left
L 69%
C 23%
Factuality
To view factuality data please Upgrade to Premium
